Counterfeit rabies vaccine seized in Delhi, supply traced to Kanpur
The Delhi Drugs Control Department seized 481 units of counterfeit Abhayrab rabies vaccine worth Rs 2 lakh during raids on three premises of a firm in Central Delhi's Bhagirath Palace, a government release said on Monday. Of the stock, 120 vials were sent as legal samples to the Central Research Institute, Kasauli. Human Biologicals Institute, Telangana, confirmed the batch was counterfeit. The supply was traced to an agency in Kanpur.
Source
Indian Express — Cities · read the original report ↗
Desk check · compared with the source
What the desk checked (5)
- Counterfeit rabies vaccine worth Rs 2 lakh was seized from a firm in Bhagirath Palace, Central Delhi. — Attributed to a government release cited as issued on Monday; figure appears in source.
- 481 units of Purified Vero Cell Rabies Vaccine (Abhayrab) were seized in raids on three premises. — Figure appears in source body, but the source headline states 418 units — internal inconsistency an editor must resolve.
- 120 vials were sent as legal samples to the Central Research Institute, Kasauli; 361 units and seven invoices seized under the Drugs and Cosmetics Act, 1940. — Figures appear in source, attributed to the DDC department; 120 plus 361 equals 481, consistent with the body figure.
- Human Biologicals Institute, Telangana, a division of IIL, confirmed the batch was counterfeit and not released by the company. — Attributed to the manufacturer in the source.
- An ICMR study published in The Lancet Infectious Diseases in 2025 estimated 5,726 human rabies deaths in India annually, based on a survey of nearly 79,000 households. — Attributed to a named study and journal in the source; not independently verified here.
Analysts’ view opinion
This is, at its core, a Drugs and Cosmetics Act, 1940 matter — the statute reserves its harshest penalties for the manufacture, sale and stocking of spurious drugs. It is no accident that the Delhi Drugs Control Department lifted 120 vials as "legal samples" and sent them to the government laboratory at Kasauli: under the statutory scheme, it is the Government Analyst's report that carries evidentiary weight in a prosecution. The manufacturer's confirmation that it never released the batch is a powerful indicator, but what will stand up in court is the statutory test result. With the supply chain running across two states, this now becomes a coordinated Delhi–Uttar Pradesh enforcement exercise.
- The seizure of 481 units plus seven purchase invoices matters legally as much as the stock itself — invoices are the documentary spine for proving the chain of supply.
- In spurious-drug cases, prosecution typically follows the Government Analyst's report, so the Kasauli test outcome will shape the scope and strength of any complaint.
- The Delhi firm's claim that it sourced the stock from a Kanpur agency foreshadows a bona fide purchase-type defence, which would have to be established on evidence rather than assertion.
- Because the supply crossed state lines, questions of jurisdiction and where proceedings are instituted will need to be worked out between the Delhi and UP drug departments.
- The minister's talk of strict action signals enforcement priority, not guilt — sentencing is a matter for the courts after trial.
What to watch — Watch for the Kasauli laboratory report, the sections and named accused in any complaint filed on the strength of it, and whether Delhi and UP set up a joint investigative track.
The story does not establish any arrests, filed charges or licence cancellations, nor how many patients actually received the counterfeit vaccine — at this stage these remain allegations and no one's guilt has been adjudicated.
Deep dive
Research brief · 8 facts · 5 dates · exam-readyThe brief
Context
The Delhi Drugs Control (DDC) Department raided three premises of a firm in Bhagirath Palace, a wholesale medicine hub in Central Delhi, and seized 481 units of counterfeit Purified Vero Cell Rabies Vaccine sold under the brand Abhayrab, worth Rs 2 lakh. The original manufacturer, Human Biologicals Institute in Telangana — the human health and vaccine division of Indian Immunologicals Limited (IIL) — confirmed the batch was counterfeit and never released by the company. The firm told investigators the stock came from an agency in Kanpur, which the Uttar Pradesh State Drug Department raided and confirmed as the source. The case revives concerns about spurious drugs in India, where an ICMR study estimates 5,726 human rabies deaths each year.
Key facts
- Delhi Drugs Control Department seized 481 units of counterfeit Purified Vero Cell Rabies Vaccine (Abhayrab) worth Rs 2 lakh from a firm in Bhagirath Palace, Central Delhi.
- Raids were conducted at three premises of the firm on the direction of Delhi Health Minister Pankaj Kumar Singh.
- Of the seized stock, 120 vials were taken as legal samples and sent to the Central Research Institute, Kasauli, for testing.
- The remaining 361 units and seven purchase invoices were seized under relevant sections of the Drugs and Cosmetics Act, 1940.
- Human Biologicals Institute, Telangana — vaccine division of Indian Immunologicals Limited — confirmed the batch was counterfeit and not released by the company.
- The UP State Drug Department raided two locations, including the Kanpur agency's premises, and confirmed it was the source of supply to Delhi.
- On August 27, the Drugs Controller General of India wrote to all state drug control departments to step up vigilance on movement and distribution of a misbranded vaccine batch.
- A 2025 ICMR study in The Lancet Infectious Diseases, based on a survey of nearly 79,000 households, estimated 5,726 human rabies deaths in India annually; dogs caused three of every four animal bites.
Timeline
- August 27Drugs Controller General of India writes to all state drug control departments to increase vigilance on the movement, distribution and availability of a misbranded vaccine batch.
- 2025ICMR study published in The Lancet Infectious Diseases estimates 5,726 annual human rabies deaths in India.
- Date not stated in the sourceDDC raids three premises of a Bhagirath Palace firm; seizes 481 units of Abhayrab; 120 vials sent to CRI Kasauli; 361 units and seven invoices seized.
- After the Delhi seizureFirm names a Kanpur agency as its source; UP State Drug Department raids two locations and confirms the source.
- Monday (day of the release)Government release announces the seizure and the tracing of supply to Kanpur; DDC says it is tracing the distribution network.
Who has a stake
- Delhi Drugs Control (DDC) Department — Conducted the raids and seizures; now tracing the wider distribution network of the counterfeit vaccine.
- Delhi Health Minister Pankaj Kumar Singh — Ordered the raids; asserts a zero-tolerance policy on spurious medicines for cancer, rabies and TB, including suppliers outside Delhi.
- Indian Immunologicals Limited / Human Biologicals Institute, Telangana — Brand owner and manufacturer of Abhayrab; confirmed the batch was counterfeit and says authorised-channel supplies are unaffected.
- Uttar Pradesh State Drug Department — Raided two locations in the state and confirmed the Kanpur agency was the source of the Delhi supply.
- Central Research Institute, Kasauli — Testing laboratory to which 120 vials were sent as legal samples, key to establishing evidence.
- Drugs Controller General of India (DCGI) — National regulator that had already alerted all states to a misbranded vaccine batch.
- Patients and animal-bite victims — Risk of death from rabies if injected with fake vaccine; rabies is described as fatal and serious.
Why it matters
A counterfeit rabies vaccine is not merely a commercial fraud: rabies is almost invariably fatal once symptoms appear, so a fake vial can cost a bite victim their life while giving false assurance. The seizure shows fake biologicals moving across state lines through wholesale hubs, testing the coordination between state drug controllers and the central regulator. With an estimated 5,726 human rabies deaths in India each year, the integrity of the post-bite vaccine supply chain is a direct public health question.
UPSC angle
Prelims pointers
- Abhayrab is a Purified Vero Cell Rabies Vaccine; its manufacturer is Human Biologicals Institute, Telangana, the human health and vaccine division of Indian Immunologicals Limited (IIL).
- Seizures of spurious drugs are made under the Drugs and Cosmetics Act, 1940.
- Central Research Institute (CRI), Kasauli, tests legal drug samples; 120 vials were sent there in this case.
- The Drugs Controller General of India (DCGI) alerted all state drug control departments on August 27 about a misbranded vaccine batch.
- A 2025 ICMR study in The Lancet Infectious Diseases estimated 5,726 human rabies deaths annually in India, based on nearly 79,000 households surveyed.
- Dogs accounted for three out of every four animal bites, per the ICMR study.
Mains framing
The Delhi seizure of 481 counterfeit Abhayrab vials, traced through a Bhagirath Palace firm to a Kanpur agency, illustrates how spurious biologicals penetrate India's fragmented pharmaceutical distribution chain. Causes visible in the source include the presence of large unregulated-looking wholesale markets, invoice trails that need forensic reconstruction (seven purchase invoices were seized), and inter-state supply routes that fall between two state drug departments' jurisdictions. The implications are severe because rabies is fatal and post-exposure prophylaxis offers no second chance; a fake vial converts a treatable exposure into a probable death, and with an estimated 5,726 annual rabies deaths the margin for error is nil. The response pattern in the source suggests a workable template: manufacturer verification of batch authenticity (IIL/HBI confirming non-release), independent laboratory testing at CRI Kasauli, a DCGI advisory to all states to raise vigilance, and cross-state enforcement coordination between Delhi and Uttar Pradesh. The way forward, on the evidence available, lies in tracing the full distribution network as DDC says it is doing, pursuing suppliers outside Delhi as the Health Minister has promised, prosecution under the Drugs and Cosmetics Act, 1940, and strengthening batch-level traceability so that purchases through authorised hospitals and licensed pharmacies remain the only viable channel.
Key terms
- Counterfeit/spurious drug
- A medicine falsely presented as a genuine branded product; here a vaccine batch that the manufacturer confirmed it never released.
- Purified Vero Cell Rabies Vaccine (PVRV)
- A cell-culture rabies vaccine; Abhayrab is the brand seized in this case.
- Drugs and Cosmetics Act, 1940
- The law under which the remaining 361 vials and seven purchase invoices were seized.
- Drugs Controller General of India (DCGI)
- India's central drug regulator, which on August 27 asked states to raise vigilance on a misbranded vaccine batch.
- Central Research Institute, Kasauli
- Government institute where the 120 legal sample vials were sent for testing.
- Legal sample
- A portion of seized stock formally collected and sent for laboratory testing to serve as evidence in prosecution.
Practice questions
- Counterfeit vaccines expose gaps in India's pharmaceutical supply chain. Examine the regulatory architecture involved — from state drug control departments to the DCGI — and suggest measures to strengthen batch-level traceability.
- Despite the availability of effective post-exposure prophylaxis, India records thousands of rabies deaths annually. Discuss the reasons, drawing on the 2025 ICMR estimate of 5,726 deaths a year.
- Inter-state movement of spurious drugs raises questions of enforcement coordination. Using the Delhi-Kanpur case, analyse how federal coordination in drug regulation can be improved.
Grounded only in the source report — figures and dates are the source's, not inferred.